HIV-1 non-nucleoside reverse transcriptase inhibitors
| Autor: | Iain Morrison, Marita Högberg |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Pharmacology
Nevirapine Efavirenz business.industry virus diseases General Medicine biochemical phenomena metabolism and nutrition Virology Reverse transcriptase Nucleoside Reverse Transcriptase Inhibitor Loviride chemistry.chemical_compound chemistry immune system diseases Abacavir Trovirdine Drug Discovery medicine Delavirdine business medicine.drug |
| Zdroj: | Expert Opinion on Therapeutic Patents. 10:1189-1199 |
| ISSN: | 1744-7674 1354-3776 |
| Popis: | Two classes of anti-HIV drugs are currently marketed which target the HIV-1 reverse transcriptase (RT). The first explored class was the nucleoside RT inhibitors (NRTIs), such as AZT, ddI, ddC, 3TC, D4T and abacavir, whereas the more recently launched class are the non-nucleoside RT inhibitors (NNRTI) currently comprising nevirapine (Viramune™, Boehringer Ingelheim), delavirdine (Rescriptor™, Pharmacia and Upjohn) and efavirenz (Sustiva™, Dupont Pharmaceuticals). The NNRTI class is in rapid development to find more clinically useful inhibitors, especially against inhibitor-induced mutant RT enzymes. This article covers development in the area of HIV-1 NNRTI from 1997 through early 2000. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|